Publications by authors named "K Parodi"
PET has become an important clinical modality but is limited to imaging positron emitters. Recently, PET imaging withZr, which has a half-life of 3 days, has attracted much attention in immuno-PET to visualize immune cells and cancer cells by targeting specific antibodies on the cell surface. However,Zr emits a single gamma ray at 909 keV four times more frequently than positrons, causing image quality degradation in conventional PET.
View Article and Find Full Text PDFOrthotopic tumor models in pre-clinical translational research are becoming increasingly popular, raising the demands on accurate tumor localization prior to irradiation. This task remains challenging both in X-ray and proton computed tomography (xCT and pCT, respectively), due to the limited contrast of tumor tissue compared to the surrounding tissue. We investigate the feasibility of gadolinium oxide nanoparticles as multimodal contrast enhancement agent for both imaging modalities.
View Article and Find Full Text PDF: To present a long short-term memory (LSTM)-based prompt gamma (PG) emission prediction method for proton therapy.: Computed tomography (CT) scans of 33 patients with a prostate tumor were included in the dataset. A set of 10histories proton pencil beam (PB)s was generated for Monte Carlo (MC) dose and PG simulation.
View Article and Find Full Text PDFArticle Synopsis
- Researchers explored ways to reduce radiation exposure from daily cone-beam computed tomography (CBCT) used in image-guided radiotherapy while maintaining image quality using deep learning algorithms.
- They tested three imaging dose levels (100%, 25%, 15%, and 10%) and used two models (cycleGAN and CUT) to create synthetic computed tomography (sCT) images from reduced dose CBCTs, specifically analyzing prostate cancer patient data.
- The results showed that cycleGAN outperformed CUT in terms of accuracy in delineating important anatomical structures, indicating that a 25% dose level is the minimum suitable imaging dose for effective radiotherapy.
Article Synopsis
- Multicentric studies face challenges with patient privacy and data security, prompting an exploration of federated analysis through secure multiparty computation.
- A pilot study involving 48 cancer patients demonstrated a successful architecture for secure data analysis that complies with stringent European regulations on patient privacy.
- The treatment led to high local control rates and low toxicity, with a median overall survival of 19 months, showcasing the benefits of privacy-friendly evaluation in clinical research.